JUN-Mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines

Mutations or deletions in exons 18–21 in the epidermal growth factor receptor (EGFR) are present in approximately 15% of tumors in patients with non-small cell lung cancer (NSCLC). They lead to activation of the EGFR kinase domain and sensitivity to molecularly targeted therapeutics aimed at this do...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Main Authors: Kani, Kian, Garri, Carolina, Tiemann, Katrin, Malihi, Paymaneh D., Punj, Vasu, Nguyen, Anthony L., Lee, Janet, Hughes, Lindsey D., Alvarez, Ruth M., Wood, Damien M., Joo, Ah Young, Katz, Jonathan E., Agus, David B., Mallick, Parag
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5558834/
https://ncbi.nlm.nih.gov/pubmed/28566434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0564
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares